Hormonal
GLP-1 receptor agonists (specifically liraglutide and semaglutide) induce clinically significant, sustained body weight reduction in individuals with overweight or obesity, with histological resolution of NASH observed in approximately 40% to 60% of patients.
If you have obesity or type 2 diabetes, GLP-1 medications like semaglutide or liraglutide are highly effective for losing weight and improving liver health (NASH). They work by mimicking a gut hormone that reduces appetite and improves blood sugar control. While they require injections (or a daily pill for semaglutide) and may cause temporary stomach issues, the weight loss benefits are substantial and sustained when combined with lifestyle changes.
The GLP- 1RAs, liraglutide and semaglutide, were associated with clinically relevant, sustained body weight reduction in individuals with overweight or obesity and without T2D... liraglutide and semaglutide led to histological resolution of NASH in ~40% to 60% of patients
Why this rating
Based on large phase II/III trials and meta-analyses, though fibrosis effects are not statistically significant.
Source
Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
A. Sidney Barritt et al. · Alimentary Pharmacology & Therapeutics · 2022
DOI 10.1111/apt.16794
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →